Abstract
Toxoplasma gondii (T. gondii, Tg) is a globally distributed parasitic protozoan causing different forms of toxoplasmosis in humans. Mast cells (MCs) play a role during T. gondii infection. Several studies suggest that MC activator compound 48/80 (C48/80) may be an effective vaccine adjuvant resulting in a potent and protective antigen-specific immune response against bacteria or virus infections. The present study was performed to determine whether C48/80 had adjuvant activity for ultraviolet (UV)-attenuated T. gondii vaccine to induce protective immune responses against T. gondii in mouse model. Kunming mice were divided into the following groups: naive mice, naive mice administrated with C48/80 intraperitoneal (i.p.) injection, mice infected by i.p. injection of 104 T. gondii RH strain alone (Tg group), mice infected with 104 RH tachyzoites plus C48/80 administration (Tg + C48/80), mice immunized with UV-Tg alone, and mice immunized with UV-Tg plus C48/80 administration (UV-Tg + C48/80). All the vaccinated mice were challenged with 104 tachyzoites of T. gondii RH strain at the same time as the primary infection. The survival rates, liver histopathologies, liver parasite burdens, and mRNA expression levels of Th1 and Th2 cytokines in the livers and spleens detected by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) were compared among the aforementioned groups after primary infection or challenge infection. The results showed that, compared to the Tg group or Tg + C48/80 group, the UV-Tg + Tg group and UV-Tg + C48/80 + Tg group had significantly prolonged survival time, lower liver histopathological scores, decreased liver parasite burdens, and increased levels of Th1 and Th2 cytokines in the livers and spleens. There was no significant difference of survival time between the UV-Tg + Tg group and the UV-Tg + C48/80 + Tg group; however, the UV-Tg + C48/80 + Tg group showed higher parasite burden, more severe liver histopathology, and decreased IL-4 level compared to the UV-Tg + Tg group. These results indicate that C48/80 had no adjuvant activity for the immunization induced by UV-attenuated T. gondii vaccine.
This is a preview of subscription content, log in via an institution to check access.
References
Bento D, Staats HF, Gonçalves T, Borges O (2015) Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. Eur J Pharm Biopharm 93:149–164. doi:10.1016/j.ejpb.2015.03.024
Cruz A et al (2014) Mast cells are crucial in the resistance against Toxoplasma gondii oral infection. Eur J Immunol 44(10):2949–2954. doi:10.1002/eji.201344185
Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M (2011) Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 41(7):1883–1893. doi:10.1002/eji.201040994
Freitas MA, Segatto N, Tischler N, de Oliveira EC, Brehmer A, da Silveira AB (2017) Relation between mast cells concentration and serotonin expression in chagasic megacolon development. Parasite Immunol 39(3) doi: 10.1111/pim.12414
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M (2005) Mast cells as ‘tunable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23:749–786. doi:10.1146/annurev.immunol.21.120601.141025
Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A (1991) Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 146(1):286–292
Gendaszewska-Darmach E, Weglowska E, Walczak-Drzewiecka A, Karas K (2016) Nucleoside 5′-O-monophosphorothioates as modulators of the P2Y14 receptor and mast cell degranulation. Oncotarget 7(43):69358–69370. doi:10.18632/oncotarget.12541
Gigley JP, Fox BA, Bzik DJ (2009a) Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J Immunol 182(2):1069–1078
Gigley JP, Fox BA, Bzik DJ (2009b) Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. Infect Immun 77(12):5380–5388. doi:10.1128/IAI.00649-09
Hill D, Dubey J (2002) Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 8(10):634–640
Huang B et al (2013) Mast cells modulate acute toxoplasmosis in murine models. PLoS One 8(10):e77327. doi:10.1371/journal.pone.0077327
Innes EA, Vermeulen AN (2006) Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology 133(Suppl):S145–S168. doi:10.1017/s0031182006001855
Jash A et al (2011) Topical application of porcine placenta extract inhibits the progression of experimental contact hypersensitivity. J Ethnopharmacol 133(2):654–662. doi:10.1016/j.jep.2010.10.054
Jones LA et al (2010) IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 40(2):426–436. doi:10.1002/eji.200939705
Jongert E, Roberts CW, Gargano N, Förster-Waldl E, Petersen E (2009) Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 104(2):252–266
Khurana S, Batra N (2016) Toxoplasmosis in organ transplant recipients: evaluation, implication, and prevention. Trop Parasitol 6(2):123–128
Liu AY et al (2013) Mast cells recruited to mesenteric lymph nodes during helminth infection remain hypogranular and produce IL-4 and IL-6. J Immunol 190(4):1758–1766. doi:10.4049/jimmunol.1202567
Lu F, Huang S (2017) The roles of mast cells in parasitic protozoan infections. Front Immunol 8:363. doi:10.3389/fimmu.2017.00363
Martins PR, Nascimento RD, de Souza LA, Martinelli PM, d’Ávila Reis D (2014) Neuroimmunopathology of Trypanosoma cruzi-induced megaoesophagus: is there a role for mast cell proteases? Hum Immunol 75(4):302–305. doi:10.1016/j.humimm.2014.02.003
McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF (2009) The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27(27):3544–3552. doi:10.1016/j.vaccine.2009.03.069
McLachlan JB et al (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14(5):536–541. doi:10.1038/nm1757
Meng S et al (2011) Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS One 6(5):e19863. doi:10.1371/journal.pone.0019863
Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. Physiol Rev 77(4):1033–1079
Tuon FF, Amato VS, Bacha HA, Almusawi T, Duarte MI, Amato Neto V (2008) Toll-like receptors and leishmaniasis. Infect Immun 76(3):866–872
Wilainam P, Nintasen R, Viriyavejakul P (2015) Mast cell activation in the skin of Plasmodium falciparum malaria patients. Malar J 14:67. doi:10.1186/s12936-015-0568-8
Wu B et al (2013) Upregulated expression of Tim-3 involved in the process of toxoplasmic encephalitis in mouse model. Parasitol Res 112(7):2511–2521. doi:10.1007/s00436-013-3416-1
Xu L et al (2014) Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5. Immunol Investig 43(3):224–235. doi:10.3109/08820139.2013.859155
Yang X et al (2010) Evaluation of the adjuvant properties of Astragalus membranaceus and Scutellaria baicalensis GEORGI in the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models. Vaccine 28(3):737–743. doi:10.1016/j.vaccine.2009.10.065
Zeng L et al (2015) Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice. Vaccine 33(8):1008–1016. doi:10.1016/j.vaccine.2015.01.013
Zhang NZ, Wang M, Xu Y, Petersen E, Zhu XQ (2015) Recent advances in developing vaccines against Toxoplasma gondii: an update. Expert Rev Vaccines 14(12):1609–1621. doi:10.1586/14760584.2015.1098539
Zheng M et al (2015) Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant. Hum Vaccin Immunother 11(2):397–406. doi:10.4161/21645515.2014.995056
Acknowledgements
This work was supported in part by grants from the Natural Science Foundation of China (nos. 81271854 and 81471973), the Science and Technology Planning Project of Guangdong Province, China (nos. 2014A020212108 and 2014A020212212), and the 2016 Medical Education Research Project of Chinese Medical Association Medical Education Branch and China Higher Education Society of Medical Education Professional Committee (2016B-KY013).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
All animal experiments were approved by the Ethical Committee of Animal Experiments of Sun Yat-sen University.
Rights and permissions
About this article
Cite this article
Li, X., Chen, S., Huang, S. et al. Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine. Parasitol Res 116, 2347–2353 (2017). https://doi.org/10.1007/s00436-017-5522-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-017-5522-y